Israel-based Cellect Biotechnology Ltd. named Andrew Sabatier as its chief business officer to head its U.S. center of operations.
Sabatier was most recently leading GE Cell Therapy's sales and market development for U.S. and Canada. Prior to joining GE, he was the sales vice president of Biosafe America Inc., a company acquired by General Electric Co.
Cellect Biotechnology is a biotechnology focused on developing technologies for selecting stem cells from any given tissue to improve a variety of related therapies.
